• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

The story of a ‘political drug’ against hepatitis C

Home > Viewpoints

The story of a ‘political drug’ against hepatitis C

17 Jun 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

This interview by Yvan Pandelé was initially published in French on Heidi News on 16 June 2021. It was translated and published in Geneva Solutions on 17 June 2021.

Malaysia, along with several Geneva-based NGOs, has developed a new antiviral drug for hepatitis C, ravidasvir. For the Drugs for Neglected Diseases initiative (DNDi), which initiated the project, the objective was clearly political: to bring down the price of the drug in a market dominated by molecules that were at the time unaffordable. Dr François Bompart, Director of the Hepatitis C Initiative at DNDi from 2018 to 2020, where he is now in charge of access to medicines, shares the story in a Q&A.

Heidi.news – How did this drug, ravidasvir, come about?

François Bompart – It goes back to around 2013. At that time, sofosbuvir, a new drug against hepatitis C produced by Gilead, was introduced. From a medical point of view, it was a revolution: the virus was totally suppressed, and patients were cured, with a very well-tolerated treatment and over a very short period of time, from three to six months. But this drug was sold at around 80,000 dollars per patient, a price that was unheard of at the time. It was like a lightning strike, which really caused a scandal.

And that’s why DNDi started developing a competing drug.

We asked ourselves what we could do about it, from an activist perspective. DNDi‘s R&D Director at the time (Dr Shing Chang, ed.) went looking for interesting molecules and identified ravidasvir, produced by a Californian biotech company called Presidio. We entered into an agreement with them and an Egyptian pharmaceutical company (Pharco) to develop the drug, on the condition that it would be made available at a low price to middle-income countries. That is, those who are not rich enough to pay the price of industrialised countries, and not “poor” enough to benefit from voluntary licensing agreements.

What was the point of Presidio selling its drug at a modest price?

At the time, they were only at the stage of small studies on healthy volunteers, so they were happy that we were interested in them and that we were helping them develop the drug. The market for direct-acting antivirals against hepatitis C turned out not to be as lucrative as some people had initially thought, which makes it difficult to raise money. They also retained the rights for industrialised countries, in Western Europe and North America, so it’s still interesting for them.

That’s where Malaysia comes in?

Yes, that’s right. Malaysia was attractive to us because it was a country that had a real political will to tackle hepatitis C. It must also be said that they have approximately 400,000 sick people there (1.25 per cent of the population, ed.). The big problem with this disease is that there are very few political decision-makers, let alone financial decision-makers, who are sensitive to it. In Malaysia, the important decision-makers are getting involved. They also have a well-developed health system and good scientists. We approached them when they were in the process of designing a national hepatitis C strategy.

Several Geneva-based NGOs were also involved in the project…

Yes, DNDi set up this clinical trial in partnership with the Malaysian government, with funding from MSF. Diagnosing hepatitis is a cumbersome, three-step process that requires money and staff, with the risk of losing many patients. With the help of the NGO Find, our alter ego for diagnosis, Malaysia was able to move diagnosis from large teaching hospitals to local frontline hospitals. And this work was funded by Unitaid, also based in Geneva. It all synergized together.

Timeline

  • 2013-2014: the U.S. drug company launches sofosbuvir (Sovaldi), the first direct-acting antiviral against hepatitis Co.
  • 2016: DNDi launches trials to develop ravidasvir, a competing antiviral to sofosbuvir.
  • 2017: A standoff between Malaysia and Gilead allows Kuala Lumpur to lower the price of sofosbuvir from the negotiated floor price of $12,000 to $300, by issuing a compulsory license
  • June 2017: completion of the ravidasvir-sofosbuvir clinical trial (phase 2-3) in Malaysia
  • 2021: publication of ravidasvir results in The Lancet

In 2016, you found yourself developing ravidasvir in Malaysia… in combination with Gilead’s sofosbuvir, your initial target. Why did you make this choice?

For scientific reasons. You always need two molecules with different viral targets to treat hepatitis C, a bit like anti-HIV “cocktails”. We looked at all the compatible antivirals and the unanimous conclusion was that the sofosbuvir was the best, and it was already fully developed so we were reassured about the safety profile and the dose to be given. This gave us the best chance of developing our drug successfully.

How did this somewhat unnatural marriage work out? Did you go knocking on Gilead’s door?

I believe there have been informal contacts with Gilead, which have not led to anything. But since we were in the framework of a clinical trial, we could acquire the molecule via generic manufacturers, without going through the license holder. This is what we did, by going through the Egyptian laboratory, Pharco, to obtain the drug.

This was also the context of a 2017 standoff between Malaysia and Gilead over the price of sofosbuvir – which Kuala Lumpur won.

There are regulations in international agreements that in the event of a health emergency, a government can impose the temporary lifting of patents. Malaysia has announced its intention to buy sofosbuvir from a generic company without Gilead’s approval. This is an indirect effect of DNDi‘s presence, of R&D work and advocacy around hepatitis C. All of this made Malaysia consider it important enough to dare playing the compulsory license trick.

In response to this announcement, the company abruptly decided to grant a voluntary license to Malaysia – as well as to Thailand, Belarus and Ukraine, where trials were also planned. In Malaysia, this resulted in a reduction in the cost of sofosbuvir treatment from $12,000 to $300 per patient.

The results of the ravidasvir-sofosbuvir trial have just been published in The Lancet. What about it?

Yes, it was a trial on 300 patients that gave very high cure rates, in the order of 97 per cent. There are also interesting results in patients co-infected with HIV. We still have to be careful, it’s early in the life of the drug. But we think it is a little better than the reference treatment currently used in Malaysia in patients with genotype 3, the most difficult to treat. This represents half of the patients in the country, which has just granted conditional approval for the treatment.

What is your assessment of this effort?

At DNDi, we usually work on drugs that do not yet exist because there is no market for them. This was not the case there: at most, one could say that the world did not need a new hepatitis C drug. We invested to challenge the status quo, with the hope that ravidasvir would demonstrate some clinical superiority. It’s too early to tell, but it gave us the legitimacy to put the issue of antiviral pricing on the table. Fundamentally, it’s a political drug.

Box: Expensive antivirals for hepatitis C

When not cured spontaneously, hepatitis C can degenerate over decades, causing cirrhosis and liver cancer. It affects an average of 1 per cent of the population worldwide. The arrival of direct-acting antivirals from the end of 2013 turned the management of this viral disease on its head, making it finally curable. Currently, the market is dominated by two American laboratories: Gilead and Abbvie. In Switzerland, a treatment against hepatitis C (a combination of two antiviral drugs for three months) costs about 30,000 francs per person —reimbursed by the health insurance without restriction, but only since 2017.

Box: Voluntary or compulsory license, what’s that about?

The use of a drug falls under the intellectual property regime. In order to obtain a generic drug, which is less expensive, countries must get the explicit agreement of the patent holder via a so-called voluntary licensing scheme. This leaves the patent holder free to set whatever conditions it wishes, or even to refuse to enter into the agreement. This is sometimes the case for middle-income countries.

To get around this problem, a system of compulsory licenses was set up in the wake of the 2001 Doha Declaration. It allows a generic drug to be used without the agreement of the original patent holder in the event of a public health emergency. But using this tool has a political cost. Industrialised countries, particularly the United States, tend to fiercely defend the interests of their pharmaceutical industry if they feel that these are threatened.

Photo credit: Abang Amirrul Hadi – DNDi

Hepatitis C Asia Malaysia

Read, watch, share

Loading...
Doctor with patient
News
5 Jun 2023

Marking DNDi’s 20th year of driving medical innovation for the most neglected

Mother and child smiling
News
1 Jun 2023

Statement from Dr Luis Pizarro, Executive Director of DNDi, about the Princess of Asturias Award for International Cooperation

Statements
24 May 2023

DNDi interventions at the 76th World Health Assembly

Statements
19 May 2023

DNDi’s briefing note for 76th World Health Assembly

Viewpoints
14 Apr 2023

Bringing Chagas disease care closer to people who need it

Mother standing in front of her adolescent son
Stories
13 Apr 2023

Diagnosis & treatment closer to patients

Woman holding pills in her hand
Press releases
12 Apr 2023

Publication demonstrates how equitable deals for access to medicines can be signed with pharmaceutical industry

Researchers in lab environment
Press releases
7 Apr 2023

eWHORM project launched to eliminate worm infections in Sub Saharan Africa

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo